| Similar Articles |
|---|
 |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders.   |
The Motley Fool
June 21, 2005
Charly Travers |
A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire. |
The Motley Fool
July 25, 2005
Charly Travers |
Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged? |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
The Motley Fool
February 24, 2005
Charly Travers |
Transkaryotic's Turnaround This biotech spotlights superb management creating shareholder value. |
The Motley Fool
January 26, 2005
John Bluis |
Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease. |
The Motley Fool
November 11, 2004
Marko Djuranovic |
Take a Shot on CancerVax? The company still isn't profitable, but big gains may be on the horizon for this biotech. |
The Motley Fool
May 1, 2006
Rich Duprey |
Searching for Profits in R&D: Part 1 Here's why treating R&D as an investment can lead you to some up-and-coming small caps worthy of your investment dollars. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
The Motley Fool
August 9, 2005
Seth Jayson |
The Investor's Frame of Mind Curiosity is the successful investor's prime attribute. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
March 4, 2005
Rich Duprey |
Home Run Stocks You Already Own Boost your returns without reinventing the wheel. A familiar name in which you've already invested can be the catalyst to charge your portfolio with market-beating returns. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
The Motley Fool
October 21, 2004
W.D. Crotty |
One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
The Motley Fool
July 7, 2010
Brian Orelli |
That's Gotta Hurt: Recommending the Competition Supply constraints continue to plague Genzyme. |
Pharmaceutical Executive
June 1, 2012 |
Raising the Stakes in CNS As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory. |
The Motley Fool
January 9, 2006
Jim Gillies |
Be Not Afraid Don't let fear keep you from market-beating returns. Fear of losses. Fear of admitting a mistake. Fear of being left behind. Fear of buying a "loser." All of these fears can hobble an investor. Face your fears -- and beat the market. |
The Motley Fool
August 20, 2007
Brian Lawler |
Are These Perfect Pharma Acquisitions? Weighing recent drug-industry deals' odds of success: AstraZeneca and MedImmune... Shire and New River Pharmaceuticals... Gilead and Myogen... |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
The Motley Fool
October 7, 2004
Seth Jayson |
Painless? My Assets Another warning from dental tech firm Biolase Technology sends the stock down. |
Pharmaceutical Executive
October 1, 2005 |
Thought Leader: Room for Improvement An interview with Randal J. Kirk, founder of New River Pharmaceuticals, whose drug technology team has made it its goal to introduce safer, more efficacious and reliable models of existing franchise drugs. |
